Apparently with the last one day moratorium they were able to confirm a false positive and get back to shooting safely after only one day off, this never added up to me! How can they be sure it was a flase positive after only one day? when on their own website the FSC states: Performers must wait 14 days from the last sexual contact with the positive performer before retesting.
So, I decided to ask James Deen of APAC to assist me with comprehending this timeline and here is his response:
their main issue on this is that they referred to this as a moratorium when it was not. this was a 2 day confirmatory hold on production. they are able to verify that it was a false positive because within the 14 days prior to this she had a negative test. so…
day 1 – negative test
day 14 – positive test
day 14/15/16 – negative test
the 14 day incubation period has already occurred. them calling production hold at the first sight of a possible hiv was something apac fought hard for. they certainly should not have called it a moratorium
To recap August 28, 2014 FSC calls moratorium due to positive HIV test and August 29, 2014 calls moratorium off because they confirmed the false positive. So, I had to ask just how does the FSC and Cutting Edge Testing confirm the false positive? After many inquiries I found out that CET uses the HIV 1 PCR Quantitative test to confirm false positives in the adult industry.
There are two HIV1 RNA PCR Quantitative tests on the market, Abbott m2000 and Roche COBAS TaqMan. Cutting Edge Testing states that they use the Roche COBAS AmpliPrep/COBAS Taqman HIV test and goes on to say that it’s FDA approved for detection of HIV-1 RNA Viral load. So, I did my homework on both tests and found the following:
The Abbott RealTime HIV-1 assay is an in vitro reverse transcription-polymerase chain reaction (RT-PCR) assay for the quantitation of Human Immunodeficiency Virus type 1 (HIV-1) on the automated m2000 System in human plasma from HIV-1 infected individuals over the range of 40 to 10,000,000 copies/mL. The Abbott RealTime HIV-1 assay is intended for use in conjunction with clinical presentation and other laboratory markers for disease prognosis and for use as an aid in assessing viral response to antiretroviral treatment as measured by changes in plasma HIV-1 RNA levels. This assay is not intended to be used as a donor screening test for HIV-1 or as a diagnostic test to confirm the presence of HIV-1 infection.
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is an in vitro nucleic acid amplification test for the quantitation of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in human plasma using the COBAS® AmpliPrep Instrument for automated specimen processing and COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer for automated amplification and detection.
This test is intended for use in conjunction with clinical presentation and other laboratory markers of dis ease progress for the clinical management of HIV-1 infected patients. The Test can be used to assess patient prognosis by measuring the baseline HIV-1 RNA level or to monitor the effects of antiretroviral therapy by measuring changes in EDTA plasma HIV-1 RNA levels during the course of antiretroviral treatment.
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test is not intended for use as a screening test for the presence of HIV-1 in blood or blood products or as a diagnostic test to confirm the presence of HIV-1 infection.
In conclusion, I have some serious issues with the way performer health and safety has been handled by the FSC up to this point. Performers need to be more aware of what risks they are taking and better informed about what methods are being used because,”the latest cutting-edge testing” isn’t enough information for anyone to make an informed decision. It’s time that performers are educated about STDs and HIV. There should be some literature made available to performers about how to identify an STD, how to prevent transmission of STDs and vaccinations, and where to get free or inexpensive treatment for STDs! Keeping performers in the dark is hurting the entire industry, and now with all the escorting going on (male and female),hurting the general public!
Please note that Talent Testing Services did give me a different answer than CET & FSC and agreed that the HIV RNA Quantitative assay test is used in patient management in order to determine viral load in already diagnosed cases. TTS states that they use an algorithm in order to discard any possibility of false positives including, but not limited to, repeating the test with a different sample.
Maybe the adult industry needs to have a standard of testing that is the same across the board and has full disclosure to all performers about the types of testing being performed, after all it is the performers’ health on the line here!
THE ADULT INDUSTRY NEEDS BETTER HEALTH AND SAFETY PRACTICES AND BETTER ON SET PROTOCOL. I consider myself to be the unofficial spokesperson for this change and I am not giving up or going away! I am not getting paid for my time and effort; I am doing it because I actually care and someone has to stand up for performer rights! I am not getting paid off by some foundation or production company to tell you false truths… like so many others! I urge you all to be more aware of what you’re getting yourself into and stand up for your right to work in a safe work environment! Don’t get pressured into taking risks for monetary gain because the treatment and time off work will cost you more in the long run!